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Abstract 
Galactokinase catalyses the first committed step of the Leloir pathway, i.e. the ATP-dependent 
phosphorylation of α-D-galactose at C1-OH.  Reduced galactokinase activity results in the inherited 
metabolic disease type II galactosemia.  However, inhibition of galactokinase is considered a viable 
approach to treating more severe forms of galactosemia (types I and III).  Considerable progress has 
been made in the identification of high affinity, selective inhibitors.  Although the structure of 
galactokinase from a variety of species is known, its catalytic mechanism remains uncertain.  While 
the bulk of the evidence suggests that the reaction proceeds via an active site base mechanism, 
some experimental and theoretical studies contradict this.  The enzyme has potential as a biocatalyst 
in the production of sugar 1-phosphates.  This potential is limited by its high specificity.  A variety of 
approaches have been taken to identify galactokinase variants which are more promiscuous.  These 
have broadened galactokinase’s specificity to include a wide range of D- and L-sugars.  Initial studies 
suggest that some of these alterations result in increased flexibility at the active site.  It is suggested 
that modulation of protein flexibility is at least as important as structural modifications in 
determining the success or failure of enzyme engineering. 
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Introduction:  Galactokinase 
Galactokinase (galactose kinase, E.C. 2.7.1.6) is a member of the GHMP kinase family.  This family of 
small molecule kinases phosphorylate a variety of small molecule substrates at the expense of ATP.  
The GHMP kinase family is named after the four originally identified members:  galactokinase, 
homoserine kinase, mevalonate kinase and phosphomevalonate kinase [1,2].  Further members of 
the superfamily have been discovered subsequently and these include N-acetylgalactosamine 
kinase, galacturonic acid kinase, arabinose kinase and pantoate kinase [3-7].  Two non-enzymatic 
family members – the Caenorhabditis elegans sex-fate determining protein XOL-1 and 
Saccharomyces cerevisiae transcriptional regulator Gal3p – have also been recognised as family 
members [8-10].  Proteins in the family have three highly conserved motifs.  Motif I is involved in 
binding of the small molecule substrate, motif II in binding of the nucleotide triphosphate and motif 
III in catalysis [1].  The sequences in between these conserved motifs vary in terms of residues and 
length but the overall fold of these proteins is similar [11]. 
Galactokinase catalyses the first committed step of the Leloir pathway, the magnesium dependent 
phosphorylation of α-D-galactose at position 1 of the sugar ring [12,13].  The function of the Leloir 
pathway is to convert galactose into glucose 1-phosphate (Figure 1).  This compound is then 
isomerised into galactose 6-phosphate which can enter glycolysis.  The pathway is especially 
important in young mammals since the main sugar in milk is lactose, a disaccharide of glucose and 
galactose. 
 
Galactokinase deficiency:  type II galactosemia 
Dysfunction of any of the enzymes encoding enzymes of the Leloir pathway results in the autosomal 
recessive disorder galactosemia (Figure 2).  This inherited metabolic disorder presents as a 
decreased ability to metabolise galactose [14,15].  There are three types of galactosemia each 
resulting from a mutation in a gene encoding a different enzyme of galactose metabolism.  Type I 
galactosemia or classical galactosemia (OMIM #230400) is caused by mutations in the gene encoding 
galactose-1-phosphate uridylyltransferase (GALT; EC 2.7.7.12).  Short term symptoms include 
vomiting, diarrhoea and sepsis.  Longer term symptoms include speech impairments, cognitive 
disabilities, female reproductive problems and liver problems [14,16]. Approximately 200 disease-
associated variants of GALT are known with these alterations spread throughout the sequence and 
structure [16,17]. 
Type II galactosemia (OMIM#230200) results from mutations in the GALK1 gene which encodes 
galactokinase [18,19].   These mutations can be insertions, deletions and single base changes [20-
25]. The main symptom of this type of galactosemia is early onset cataracts [20]. The condition is 
treated by surgery to remove the cataracts combined with the exclusion of galactose and lactose 
from the diet. Since galactose cannot be metabolised it builds up in the cells of patients.  In the lens 
cells of the eye, galactose is efficiently converted to its corresponding alcohol galactitol (dulcitol) by 
the action of aldose reductase (EC 1.1.1.21). It has been shown in a mouse model that galactitol 
builds up, changing osmotic pressure and causing cell lysis [26]. No long-term complications have 
been definitively associated with this condition [27].  Thus, type II galactosemia is regarded as the 
most benign of the three types.  In vitro studies on purified, recombinant galactokinase 
demonstrated a rough correlation between disease severity and effects on the enzyme [25,28].  In 
general, those variations associated with the most severe forms of the disease (cataracts developing 
within the first few months of life) resulted in proteins which were insoluble on expression in 
Escherichia coli.  Consequently, it was not possible to isolate these proteins and study their 
enzymological properties.  However, this suggests that these variants are misfolded and may well 
aggregate into insoluble, inactive complexes in vivo [28].  Those variants associated with 
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intermediate phenotypes (cataracts developing childhood) were soluble on expression in E. coli and 
had impaired kinetic parameters compared to the wild-type protein [28].  One variant, p.A198V, had 
enzyme kinetic properties which were essentially identical to the wild-type [28].  This variant is 
relatively common in East Asian populations and is associated with an increased risk of cataracts in 
mid-life [24].  Cells expressing this variant have lower amounts of galactokinase protein compared to 
those expressing the wild-type enzyme.  This suggests that the protein is less stable under cellular 
conditions [24]. 
Type III galactosemia (OMIM#230250) results from mutations in the gene encoding UDP-galactose 
4’-epimerase (GALE; EC 5.1.3.3) GALE [29].  This enzyme converts UDP-galactose to UDP-glucose 
(Figure 1).  This is most likely the rarest form of galactosemia and the disease manifestations vary 
greatly in severity.  The mildest forms are almost asymptomatic, resulting only in alterations in blood 
chemistry whereas the most severe cases are comparable to the worst cases of type I galactosemia.  
Complete removal of galactose from the diets of these patients is not advised.  Since GALE is 
defective in this disease, UDP-galactose cannot be produced from glucose. This compound is 
required for the biosynthesis of glycolipids and glycoproteins.  It is important therefore that 
galactose in the diet is present but carefully controlled [14]. 
The molecular pathology of galactosemia remains somewhat mysterious.  There is considerable 
evidence that galactose 1-phosphate accumulation is toxic to cells, although the mechanism of this 
toxicity is unknown [30,31].  It has been proposed that inhibition of galactokinase may be beneficial 
in type I galactosemia (and severe forms of type III galactosemia) since this would reduce the 
accumulation of galactose 1-phosphate [27].  Potentially, this would “convert” type I and type III 
galactosemia into the much less severe type II (Figure 2).  If this hypothesis is correct then these two 
life-threatening conditions which result in significant physical and cognitive disabilities could be 
significantly mitigated.  It is likely that patients would have to continue on galactose (and lactose) 
restricted diets and may also require cataract removal at some point.  However, they may be able to 
lead otherwise normal lives. 
The identification of high affinity, selective inhibitors of galactokinase is challenging.  The only 
naturally occurring inhibitors known are the substrate galactose and the product galactose 1-
phosphate [28,32].  Neither would be suitable therapeutically and both have relatively low affinities.  
The similarity of the GHMP kinase family members also presents a problem.  While there is some 
variation in the small molecule substrate site, the ATP binding site is well-conserved.  A particular 
problem is presented by N-acetylgalactosamine kinase (GALK2; EC 2.7.1.157).  This enzyme has a 
highly similar active site and also has low levels of activity against galactose [33,34].  The similarity to 
other GHMP kinases, especially GALK2, results in a risk of off-target effects.  However, any drug used 
to treat galactosemia needs to be well-tolerated over a long period of time.  It is likely that patients 
would need to take the drug regularly throughout childhood and, quite possibly, for the duration of 
their lives. 
Through high-throughput screening a number of promising inhibitors of galactokinase have been 
identified [35,36].  An initial screen identified 34 compounds, with a variety of chemical scaffolds 
which had micromolar IC50 values [37].  Three of these compounds showed selectively for 
galactokinase over mevalonate kinase and were also capable of reducing galactose 1-phosphate 
levels in cells [38].  A second screen identified another 200 inhibitors.  From these a 4-oxo-3,4-
dihydro-2H-1,3-thiazine-5-carbonitrile scaffold was used as the basis for further optimisation 
resulting in compounds with IC50 values in the low micromolar range [39].  Subsequent work resulted 
in the discovery of a spiro-benzoxazole compound which inhibited galactokinase, but had no activity 
against GALK2 [40].  Work on the identification of galactokinase inhibitors has also been assisted by 
molecular dynamics simulations of protein-inhibitor complexes [41]. 
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Structure and mechanism of galactokinase 
The crystal structure of human galactokinase has been solved. The enzyme has two domains:  an N-
terminal domain with a long α-helix composed of 15 residues alongside a 6-stranded mixed β-sheet 
and a C-terminal domain with six α-helices and two layers of β-sheet each containing four strands 
[42].  Structures from other species have also been solved, including Saccharomyces cerevisiae, 
Pyrococcus furiousus and Lactococcus lactis [43-45].  These proteins, from widely different parts of 
the tree of life, have broadly similar structures to the human enzyme. 
Human galactokinase is specific to α-D-galactose, 2-deoxy-α-D-galactose and α-D-galactosamine [46].  
It is believed that only the first of these three compounds is a physiologically relevant substrate.  
Interestingly, galactokinases from different species have different kinetic mechanisms.  Human, pig, 
rat, yeast and Bifidobacterium bifidum galactokinases all operate via an ordered ternary complex 
mechanism in which ATP binds first [28,47-50].  The enzymes from fenugreek seeds and Vicia fabia 
(broad bean) also have ordered mechanisms; however, galactose binds first [51,52].  It is interesting 
to speculate that this might be the case for all plant galactokinases.  In the case of Escherichia coli 
galactokinase, the enzyme operates via a random ternary complex mechanism in which the two 
substrates can bind in any order [53].  It is not currently known what structural and dynamic features 
of the enzyme result in these different mechanisms.  Only very limited changes have been detected 
when x-ray crystal structures of the enzyme with and without substrates are compared [42]. 
GHMP kinases appear to act by at least two different catalytic mechanisms [2,20]. The majority are 
thought to act through a catalytic base in the active site (e.g. rat mevalonate kinase [54]).  In this 
mechanism, an aspartate or glutamate residue in the active site removes a proton from the 
substrate (generally from a hydroxyl group).  This renders the substrate negatively charged, highly 
nucleophilic and thus able to attack the γ-phosphate of ATP.  This attack breaks the bond linking the 
β- and γ-phosphates of ATP, transferring the γ-phosphate to the substrate.  The active site base can 
be regenerated through loss of the proton to water, thus restoring the enzyme to its original state.  
However, homoserine kinase lacks this active site base and has an asparagine residue at the 
structurally equivalent site [55].  It is hypothesised that, in this enzyme, the active site promotes 
stabilisation of the transition state, enabling catalysis [55].  It is also possible that one of the 
negatively charged oxygens on the γ-phosphate of the ATP acts as a base, wholly or partially 
abstracting a proton from homoserine [20].  The existence of this alternative mechanism suggests 
that it is possible that transition state stabilisation also plays a role in other GHMP kinase family 
members, including galactokinase. 
The catalytic mechanism of human galactokinase is currently uncertain.  However, the structure of 
the active site resembles that of mevalonate kinase with an aspartate (Asp-186 in the human 
enzyme) appropriately positioned to act as a catalytic base.  As in many other GHMP kinase family 
members, this putative base is located close to a positively charged residue, Arg-37.  Although this 
active site architecture suggests a similar mechanism to mevalonate kinase, there is some evidence 
to the contrary.  In the S. cerevisiae enzyme there was no major effects of pH on the steady-state 
kinetic parameters and no detectable deuterium kinetic isotope effect [49].  No deuterium kinetic 
isotope effect was detected with the human enzyme either [28].  These results imply that proton 
transfer is unlikely to be an important part of the catalytic mechanism.  However, both results can be 
confounded by other effects and, consequently, should be interpreted with caution.  The aspartate 
residue has been shown to be essential to catalysis in both rat and human galactokinase [38,48,56].  
However, these results also require caution.  While alteration of Asp-186 in the human enzyme to 
either alanine or asparagine reduced activity to below detectable levels, both changes also 
destabilised the enzyme towards denaturation by the chaotropic compound urea [56].  Arg-37 was 
also shown to be essential, but again alteration of this to alanine reduced the stability of the enzyme 
[56].  Thus these losses of activity could result from either removal of key chemical groups in the 
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active site or a failure of the protein to fold correctly.  Interestingly, alteration of Arg-37 to lysine 
resulted in reduced, but not zero, activity suggesting that a positive charge at this position is 
required [56].  A detailed study on the effects of pH on the kinetic parameters of the L. lactis 
galactokinase showed effects consistent with an active site base mechanism, in which the pKa of the 
active site aspartate is approximately 6.9 (compared to its free solution value of 3.9) [57].  The role 
of the adjacent arginine residue, Arg-36, was proposed to be to reduce the pKa of the C1-OH to a 
value which enables efficient proton transfer (Figure 3) [57].  However, QM/MM studies on the 
mechanism of human galactokinase have identified three residues which are proposed to stabilise 
MgATP in the active site, Glu-174, Arg-228 and Arg-105.  These studies also suggested that the 
enzyme operates via a direct phosphorylation mechanism [58].  It seems unlikely that the bacterial 
and human enzymes act by radically different catalytic mechanisms, especially considering the high 
degree of similarities of their active sites [42,44] (Figure 3).  It is possible that elements of all 
proposed mechanisms occur, with the enzyme manipulating the pKa of active site residues and the 
substrates, stabilising the transition state and also acting on the MgATP substrate.  To date, the role 
of the sugar’s conformation and dynamics in the mechanism has been underexplored and we 
suggest that this may warrant further study. 
 
Galactokinase:  potential role in biotechnology 
Sugar 1-phosphates are important precursors for the synthesis of some drugs and drug-like 
molecules, including aminoglycoside antibiotics.  Although these occur naturally and can be purified 
from these sources, semi- of fully synthetic variants may also be useful.  Chemical synthesis of 
glycosylated compounds is technically challenging.  In part, this arises from the similar reactivity of 
the hydroxyl groups present in sugars.  In the case of the pyranose ring form of galactose, there are 
six hydroxyl groups and directing chemical modifications to just one of these is difficult with 
conventional chemical agents.  However, galactokinase is highly site-specific in the reactions it 
catalyses – only α-D-galactose 1-phosphate is produced.  However, it is also specific to galactose and 
closely related sugars.  In the case of the human enzyme only a small number of very closely related 
structures can act as substrates.  Although some bacterial galactokinases have wider specificity, the 
range of possible substrates is still somewhat limited [59]. 
One important methodology which relies on sugar 1-phosphates is in vitro glycorandomisation (IVG) 
[60,61]).  This process was developed for the production of unique variants of vancomycin (and 
other antibiotics), a drug used to treat methicillin resistant Staphylococcus aureus (MRSA).  The aim 
was to produce novel variants of the drug with enhanced activity.  However, IVG has potential as a 
process for the production of novel glycosylated products [62]. Promiscuous 
nucleotidylyltransferases (Ep) and glycosyltransferases have been engineered but a promiscuous 
sugar 1-kinase is also required [60]. Along with glycogen phosphorylases and fucokinases, 
galactokinases are a group of enzymes which catalyses phosphorylation at position 1 of the sugar 
ring.  Consequently, there have been efforts made to broaden the specificity of galactokinase while 
retaining a level of activity consistent with its use in industrial processes. 
Human galactokinase will tolerate small changes to the sugar substrate at carbon-2 but not at 
carbons 4 and 6.  Even at position 2, an N-acetyl group appears to be too large to be accommodated 
and so N-acetylgalactosamine is not a substrate [46].   Asp-46, Tyr-236 and Glu-43 are partly 
responsible for anchoring the sugar in the active site; Gly-183 and His-44 form hydrogen bonds with 
the sugar [42].  Alteration of Glu-43 and His-44 to glycine and isoleucine respectively in order to 
match the equivalent sequence in arabinose kinase resulted in insoluble protein and alterations at 
Asp-46 resulted in a soluble enzyme with no detectable activity [46].  Taken together with the data 
on disease-associated variants, these results suggest that human galactokinase is not very tolerant 
to even single amino acid changes. 
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Although E. coli galactokinase has wider substrate specificity than the human enzyme, it is still 
limited having little or no activity towards sugars with alterations are carbons 3, 4 or 6 [63].  Directed 
evolution experiments carried out on E. coli galactokinase identified a tyrosine residue (Tyr-371), 
which is distant from the active site and alteration of this residue to histidine conferred increased 
substrate promiscuity.  The increased range of substrates included both D- and L-sugars (e.g. D-
galacturonic acid, D-talose, L-altrose, and L-glucose) [64].  Alteration of another tyrosine residue (Tyr-
233; equivalent to Tyr-236 in the human enzyme) also resulted in greater promiscuity [65].  
Lactococcus lactis galactokinase has low activity against D-glucose.  Comparison of the active sites of 
E. coli and L. lactis galactokinases suggested that this was due to the presence of a methionine 
residue (Met-173) in the E. coli enzyme’s active site.  Alteration of this to leucine (the equivalent 
residue in L. lactis galactokinase) resulted in the enzyme becoming active towards D-glucose.  
Combining this p.M173L variant with the previously described p.Y371H variant resulted in an 
enzyme capable of catalysing the phosphorylation of at least 28 different monosaccharides [66].  
Bacteria expressing this variant enzyme were able to produce a variety of sugar 1-phosphates when 
fed with the appropriate precursor [66]. 
Interestingly alteration of the equivalent tyrosine in the human enzyme (Tyr-379) to histidine did not 
increase substrate range but alteration to a tryptophan, lysine, arginine, serine or cysteine did albeit 
with some reduction in overall activity [67].  The ability of a residue distant from the active site to 
influence specificity suggests that the region around Tyr-379 is able to influence the active site 
structure or dynamics.  Preliminary molecular modelling studies suggested that this may occur by a 
modulation of the flexibility of the active site.  Although this requires verification experimentally and 
from more thorough molecular dynamics studies, it is consistent with the experimental data:  a more 
flexible active site would be able to accommodate a wider range of molecules, but the increased 
mobility of active site residues may reduce the catalytic efficiency and activity [67].  Interestingly, 
human GALK2 (which has a phenylalanine residue at the equivalent position to Tyr-379) naturally 
has relatively broad specificity being able to catalyse the phosphorylation of N-acetylglucosamine 
and N-acetylmannosamine in addition to its natural substrate, N-acetylgalactosamine [68,69].  The 
active site of GALK2 is predicted to be slightly more flexible than the one in galactokinase [68]. 
 
Conclusions:  is flexibility the key? 
It is now clear that the dynamic behaviour of proteins is critically important in determining their 
function [70].  Traditionally, enzyme engineering has focussed on the alteration of structural aspects 
of the protein (e.g. the modification of active site residues to change the shape and/or chemical 
reactivity of that space).  However, the substrate specificity of enzymes can also be influenced by the 
dynamics and it appears that this may be the case with galactokinase.  Increasing the flexibility of 
the active site seems to increase the range of substrates processed.  Further experimental studies 
are required to determine the nature of this increased flexibility.  Exploitation of this enzyme as a 
biocatalyst will require more than just increasing its promiscuity.  Maintaining a reasonably high 
activity level will also be required, preferably combined with an enzyme which is stable for long 
periods of time under the conditions of industrial synthesis.  Paradoxically, it may be necessary to 
simultaneously increase the flexibility of the active site, while increasing the global, overall stability 
of the protein.  In pursuit of the latter goal, consensus methods may be a viable method to achieve 
increased stability without loss of activity [71-73].  Overall, it is clear that enzyme engineering 
methods which rely on altering structure may ultimately be limited:  more successful outcomes may 
be achieved where local and global flexibility are also considered. 
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Figure legends 
Figure 1:  The Leloir pathway.  Representative structures of the enzymes are shown next to the 
corresponding reactions.  The human structures of galactose mutarotase (GALM, 1SO0 [74]), 
galactokinase (GALK1, 1WUU [42]) and UDP-galactose 4’-epimerase (GALE, 1EK6 [75]) are shown.  
Since there is currently no structure of the human galactose 1-phosphate uridylyltransferase (GALT) 
known, the E. coli structure (1HXQ [76]) is shown for this enzyme. 
Figure 2:  Dysfunction of each of the enzymes of the Leloir pathway can result in different types of 
galactosemia.  Of these, types I and III are more severe than type II.  Inhibition of GALK1 would 
reduce the build-up of galactose 1-phosphate in galactosemia types I and III.  Thus it may be possible 
to pharmacologically convert these severe diseases into something resembling a much milder one 
[27]. 
Figure 3: Active site residues in human and bacterial galactokianses. Residues in close proximity to 
the substrates in (a) L. lactis (PDB: 1PIE; [44]) and (b) human galactokinase (PDB:  1WUU; [42]) are 
shown.  Since no crystal structure with ATP bound is available for the L. lactis enzyme, this is shown 
with inorganic phosphate (Pi). 
